- Home
- MBIO vs TCRT Comparison
MBIO vs TCRT Comparison
Compare MBIO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- TCRT
- Stock Information
- Founded
- MBIO 2015
- TCRT 1998
- Country
- MBIO United States
- TCRT United States
- Employees
- MBIO N/A
- TCRT N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- TCRT Health Care
- Exchange
- MBIO Nasdaq
- TCRT Nasdaq
- Market Cap
- MBIO 4.7M
- TCRT 3.9M
- IPO Year
- MBIO N/A
- TCRT N/A
- Fundamental
- Price
- MBIO $1.43
- TCRT $2.15
- Analyst Decision
- MBIO
- TCRT
- Analyst Count
- MBIO 0
- TCRT 0
- Target Price
- MBIO N/A
- TCRT N/A
- AVG Volume (30 Days)
- MBIO 147.7K
- TCRT 344.4K
- Earning Date
- MBIO 11-07-2025
- TCRT 08-14-2025
- Dividend Yield
- MBIO N/A
- TCRT N/A
- EPS Growth
- MBIO N/A
- TCRT N/A
- EPS
- MBIO N/A
- TCRT N/A
- Revenue
- MBIO N/A
- TCRT $6,000.00
- Revenue This Year
- MBIO N/A
- TCRT $5,680,500.00
- Revenue Next Year
- MBIO N/A
- TCRT N/A
- P/E Ratio
- MBIO N/A
- TCRT N/A
- Revenue Growth
- MBIO N/A
- TCRT N/A
- 52 Week Low
- MBIO $0.89
- TCRT $1.31
- 52 Week High
- MBIO $21.95
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- MBIO 39.31
- TCRT 41.46
- Support Level
- MBIO $1.51
- TCRT $1.67
- Resistance Level
- MBIO $1.59
- TCRT $2.44
- Average True Range (ATR)
- MBIO 0.09
- TCRT 0.30
- MACD
- MBIO -0.01
- TCRT 0.07
- Stochastic Oscillator
- MBIO 2.89
- TCRT 39.67
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.